Aura Biosciences Net Worth
Aura Biosciences Net Worth Breakdown | AURA |
Aura Biosciences Net Worth Analysis
Aura Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Aura Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Aura Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Aura Biosciences' net worth analysis. One common approach is to calculate Aura Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Aura Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Aura Biosciences' net worth. This approach calculates the present value of Aura Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Aura Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Aura Biosciences' net worth. This involves comparing Aura Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Aura Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Aura Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Aura Biosciences' net worth research are outlined below:
| Aura Biosciences had very high historical volatility over the last 90 days | |
| Net Loss for the year was (76.41 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Aura Biosciences currently holds about 122.13 M in cash with (63.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.17. | |
| Aura Biosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Aura Biosciences chief medical officer sells 110,663 in stock |
Aura Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Aura Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aura Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Aura Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aura Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aura Biosciences backward and forwards among themselves. Aura Biosciences' institutional investor refers to the entity that pools money to purchase Aura Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-06-30 | 728 K | Regency Capital Management Inc.\de | 2024-09-30 | 667.3 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 573.6 K | Decheng Capital Llc | 2024-06-30 | 515.6 K | Easterly Investment Partners. | 2024-09-30 | 413.6 K | Northern Trust Corp | 2024-09-30 | 364.3 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 292.8 K | Ensign Peak Advisors Inc | 2024-09-30 | 272.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 165.7 K | Matrix Capital Management Company, Llc | 2024-06-30 | 6.9 M | Eventide Asset Management, Llc | 2024-09-30 | 5.8 M |
Follow Aura Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 443.57 M.Market Cap |
|
Project Aura Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.31) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | (0.34) | (0.32) |
When accessing Aura Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Aura Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Aura Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Aura Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aura Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Aura Biosciences' management manipulating its earnings.
Evaluate Aura Biosciences' management efficiency
Aura Biosciences has return on total asset (ROA) of (0.3022) % which means that it has lost $0.3022 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5099) %, meaning that it created substantial loss on money invested by shareholders. Aura Biosciences' management efficiency ratios could be used to measure how well Aura Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.37. At present, Aura Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.3 M, whereas Total Assets are forecasted to decline to about 153.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.70 | 5.99 | |
| Tangible Book Value Per Share | 5.70 | 5.99 | |
| Enterprise Value Over EBITDA | (3.94) | (4.13) | |
| Price Book Value Ratio | 1.55 | 1.63 | |
| Enterprise Value Multiple | (3.94) | (4.13) | |
| Price Fair Value | 1.55 | 1.63 | |
| Enterprise Value | 400.1 M | 426.5 M |
The strategic initiatives led by Aura Biosciences' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Return On Equity (0.51) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aura Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aura Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aura Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aura Biosciences Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F3 | 29th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Aura Biosciences Earnings per Share Projection vs Actual
Aura Biosciences Corporate Management
| Richard Mountfield | Senior Quality | Profile | |
| Patrick Nealon | Senior Operations | Profile | |
| CPE MBA | Chief RD | Profile | |
| Jill MD | Chief Development | Profile | |
| Amy Elazzouzi | Interim Officer | Profile | |
| Paulo Carvalho | VP Operations | Profile | |
| Bruce MD | Senior Oncology | Profile |
Already Invested in Aura Biosciences?
The danger of trading Aura Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aura Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aura Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aura Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aura Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aura Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aura Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aura Biosciences Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aura Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aura Biosciences. If investors know Aura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aura Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Return On Assets (0.30) | Return On Equity (0.51) |
The market value of Aura Biosciences is measured differently than its book value, which is the value of Aura that is recorded on the company's balance sheet. Investors also form their own opinion of Aura Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aura Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aura Biosciences' market value can be influenced by many factors that don't directly affect Aura Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aura Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aura Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aura Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.